KECK HOSPITAL OF USC
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $51.4M
- Transactions
- 3,847
- Companies
- 40
- Average per transaction
- $13,355
Who reported the payments
| Merck | $6,165,236 |
| Pfizer | $5,619,095 |
| Genentech, Inc. | $4,701,146 |
| E.r. Squibb & Sons, L.L.C. | $3,456,610 |
| AstraZeneca | $2,544,042 |
| Gilead | $2,332,082 |
| Novartis | $2,147,247 |
| AbbVie | $1,739,024 |
| Intuitive Surgical | $1,524,207 |
| Amgen | $1,487,355 |
| Edwards Lifesciences | $1,231,503 |
| Eli Lilly | $1,044,196 |
| Takeda Pharmaceuticals U.S.A., Inc. | $980,503 |
| Life Molecular Imaging Ltd | $918,825 |
| Olympus Corporation Of The Americas | $789,655 |
| Roche TCRC, Inc. | $783,933 |
| F. Hoffmann-la Roche AG | $640,589 |
| G1 Therapeutics, Inc. | $619,316 |
| Sanofi | $608,080 |
| Janssen Research & Development, LLC | $595,460 |
| Medtronic | $572,313 |
| W. L. Gore & Associates, Inc. | $567,147 |
| Neurocrine Biosciences, Inc. | $507,300 |
| Sanofi US Services Inc. | $387,528 |
| Exelixis Inc. | $372,425 |
| Regeneron | $356,772 |
| Trillium Therapeutics USA, LLC | $323,264 |
| Biomarin Pharmaceutical Inc. | $310,840 |
| Incyte Corporation | $278,796 |
| Cvrx, Inc. | $258,392 |
| Abbott | $255,430 |
| Boston Scientific | $253,824 |
| Polarityte, Inc. | $225,387 |
| Oyster Point Pharma, Inc. | $218,909 |
| Synthes GmbH | $205,248 |
| Fujifilm Healthcare Americas Corporation | $194,495 |
| Radius Health, Inc. | $172,862 |
| Biofire Diagnostics, LLC | $165,593 |
| Shire North American Group Inc | $163,360 |
| Bristol Myers Squibb | $158,807 |